Janssen And Sanofi Keep Mum On EU Fast-Track Request Outcomes
Have Teclistamab And Nirsevimab Made The Grade For Speedy Review At The EMA?
• By Maureen Kenny
Shorter review timelines are available for innovative new therapies • Source: Shutterstock: Africa Studio 
